Akebia TherapeuticsSTU:AX9 +8.59%51 Current Ratio is 1.40 as of Mar. 2026, which is 19% below its 10-year median of 1.73. GuruFocus rates STU:AX9 with a GF Score™ of 51/100 and a GF Value™ of €1.12 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, Akebia Therapeutics ranks worse than 68.84% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Akebia Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 1.40.
Akebia Therapeutics has a current ratio of 1.40. It generally indicates good short-term financial strength.
The historical rank and industry rank for Akebia Therapeutics's Current Ratio or its related term are showing as below:
STU:AX9'
s Current Ratio Range Over the Past 10 Years
Min: 1.04 Med: 1.73 Max: 9.2
Current: 1.4
During the past 13 years, Akebia Therapeutics's highest Current Ratio was 9.20. The lowest was 1.04. And the median was 1.73.
STU:AX9's Current Ratio is ranked worse than 68.84% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs STU:AX9: 1.40
Akebia Therapeutics (STU:AX9) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Akebia Therapeutics Current Ratio Related Terms
Akebia Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AX9 vs TKNO, ORGO, SIGA: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (STU:AX9) has a Current Ratio of 1.40 as of Mar. 2026. This is 19% below median its historical median of 1.73. Over the past decade, Akebia Therapeutics' Current Ratio has ranged from 1.04 to 9.20. According to the industry distribution chart, Akebia Therapeutics ranks #685 out of 995 companies in the Drug Manufacturers industry, placing it in the top 68.8%.
Is Akebia Therapeutics' Current Ratio too high?
Akebia Therapeutics' current Current Ratio of 1.40 is 19% below median its 10-year median of 1.73. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 9.20. The Drug Manufacturers industry median Current Ratio is 2.00. Akebia Therapeutics' value of 1.40 is 30% below this industry median. Based on the distribution chart, Akebia Therapeutics ranks #685 out of 995 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Current Ratio compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #685 out of 995 companies for Current Ratio. This places Akebia Therapeutics in the lower half of its industry. The industry median Current Ratio is 2.00. Akebia Therapeutics' value of 1.40 is 30% below this benchmark. Historically, Akebia Therapeutics' own Current Ratio has ranged from 1.04 to 9.20 over the past decade. While the company's 10-year median is 1.73 vs. the industry median of 2.00, Akebia Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current Current Ratio of 1.40 is 30% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current Current Ratio is 1.40, which is 19% below median its own 10-year median of 1.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.12, compared to a current price of €0.98 — trading 12.6% below its estimated fair value. The current Current Ratio is 1.40, which is 19% below median its 10-year median of 1.73 and 30% below the Drug Manufacturers industry median of 2.00. Akebia Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Current Ratio is 1.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €0.98 is trading 12.6% below its estimated GF Value™ of €1.12.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:AX9:
Current Ratio: 1.40 (19% below median its 10-year median of 1.73)
GF Value™: €1.12 vs. price of €0.98 (12.6% below fair value)
Industry Position: 30% below the Drug Manufacturers median (#685 of 995)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
51GF Score
Get the complete analysis for STU:AX9
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 
